Assertio - ASRT Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ASRT shares.
View ASRT analyst ratings or view top-rated stocks.

3 analysts have issued 1 year target prices for Assertio's stock. Their ASRT share price forecasts range from $7.00 to $8.00. On average, they predict the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 29.8% from the stock's current price.
View analysts price targets for ASRT or view top-rated stocks among Wall Street analysts.

Assertio's stock was trading at $4.30 at the beginning of 2023. Since then, ASRT stock has increased by 34.4% and is now trading at $5.78.
View the best growth stocks for 2023 here.

Assertio saw a drop in short interest in February. As of February 28th, there was short interest totaling 5,360,000 shares, a drop of 43.2% from the February 13th total of 9,440,000 shares. Based on an average trading volume of 1,590,000 shares, the days-to-cover ratio is currently 3.4 days.
View Assertio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our ASRT earnings forecast.

Assertio Holdings, Inc. (NASDAQ:ASRT) announced its quarterly earnings results on Thursday, November, 4th. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.12. The business earned $25.47 million during the quarter, compared to analyst estimates of $22.04 million. Assertio had a net margin of 70.17% and a trailing twelve-month return on equity of 72.98%. During the same period in the previous year, the business posted ($0.36) EPS.

Hartford Multifactor Small Cap ETF holds 55,110 shares of ASRT stock, representing 0.74% of its portfolio.

Assertio updated its first quarter 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $36.00 million-$38.00 million, compared to the consensus revenue estimate of $37.59 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK).

Assertio trades on the NASDAQ under the ticker symbol "ASRT."

Assertio's stock is owned by a number of retail and institutional investors. Top institutional investors include Millennium Management LLC (1.95%), Renaissance Technologies LLC (1.71%), First Eagle Investment Management LLC (1.42%), Marshall Wace LLP (1.38%), Two Sigma Investments LP (1.17%) and American Century Companies Inc. (0.93%). Insiders that own company stock include Ajay Patel, Daniel A Peisert, Group LP Cr, James L Tyree, Karen A Dawes and Paul Schwichtenberg.
View institutional ownership trends.

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ASRT stock can currently be purchased for approximately $5.78.

Assertio (NASDAQ:ASRT) has a market capitalization of $321.25 million and generates $156.23 million in revenue each year. The company earns $109.63 million in net income (profit) each year or $1.78 on an earnings per share basis.

Assertio's mailing address is 100 South Saunders Road Suite 300, Lake Forest IL, 60045. The official website for the company is www.assertiotx.com. The company can be reached via phone at (224) 419-7106, via email at investor@assertiotx.com, or via fax at 510-744-8001.